Genome Editing x Microbiome
BioPalette is a Kobe University spinout that develops genome-edited bacteria as living medicines for microbiome-based therapeutics. Its proprietary non-cutting CRISPR base-editing technologies (Target-AID and Target-G) enable precise modification of gut microbiomes without DNA strand breaks, targeting diseases driven by microbiome dysbiosis.
Create a free account to see funding visualizations and detailed round data.
Create Free AccountSep 2020
Dec 2017
Create a free account to see which investors have funded this company.
Create Free AccountBiopharmaceutical company developing and commercializing RNAi therapeutics to treat genetically d...
Develops Gene Writing technology and non-viral delivery to create in vivo genetic medicines for m...
Clinical-stage precision medicine company developing targeted therapies for immune-mediated infla...
Developer of engineered cells as medicines to treat diseases by repairing or replacing cells for ...
China's leading mRNA biotech company developing therapeutics for cancer and infectious diseases.
Clinical-stage programmable cell therapy company developing engineered T-cell therapies for solid...
